Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00050778
Status:
COMPLETED
Last Update Posted:
2015-01-08
First Post:
2002-12-19
Brief Title:
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif in Patients With Early Active Relapsing-Remitting Multiple Sclerosis
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi